NCT07744815

Brief Summary

Gastroesophageal reflux disease (GERD) is a chronic condition with frequent symptom recurrence that may negatively affect sleep quality and quality of life. This randomized controlled study aims to evaluate whether a mobile application developed as a mobile application, combined with standard education and diaphragmatic breathing training, can reduce symptom recurrence and improve sleep quality and quality of life in patients with GERD. Participants will be randomly assigned to either an intervention group receiving the mobile application or a control group receiving standard education. Outcomes will be assessed using the GerdQ, Reflux Symptom Index (RSI), GERD-HRQL, and Insomnia Severity Index (ISI) at baseline, 2 weeks, 4 weeks, and 8 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 16, 2026

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 4, 2026

Completed
Last Updated

August 5, 2026

Status Verified

July 1, 2026

Enrollment Period

5 months

First QC Date

July 30, 2026

Last Update Submit

August 3, 2026

Conditions

Keywords

GERDMobile ApplicationSleep QualityQuality of Life

Outcome Measures

Primary Outcomes (1)

  • GERD Symptom severity

    Change from baseline in gastroesophageal reflux disease symptom severity measured using the GerdQ questionnaire and the Reflux Symptom Index (RSI). The GerdQ total score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms. The RSI total score ranges from 0 to 45, with higher scores indicating more severe reflux symptoms.

    Baseline, 2 weeks, 4 weeks, and 8 weeks

Secondary Outcomes (2)

  • GERD-Related Quality of Life

    Baseline, 2 weeks, 4 weeks, and 8 weeks

  • Sleep Quality

    Baseline, 2 weeks, 4 weeks, and 8 weeks

Study Arms (2)

Mobile Application + Standard Education

EXPERIMENTAL

Participants receive standard education plus a study mobile application that provides GERD education, lifestyle modification guidance, dietary recommendations, diaphragmatic breathing exercises, and reminder messages for 4 weeks.

Behavioral: Study Mobile ApplicationBehavioral: Standard Education

Standard Education Alone

ACTIVE COMPARATOR

Participants receive standard education for gastroesophageal reflux disease without access to the study mobile application.

Behavioral: Standard Education

Interventions

Participants receive a study mobile application providing gastroesophageal reflux disease education, lifestyle modification guidance, dietary recommendations, diaphragmatic breathing exercises, and reminder messages for 4 weeks.

Mobile Application + Standard Education

Participants receive standard education for gastroesophageal reflux disease.

Mobile Application + Standard EducationStandard Education Alone

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 to 60 years.
  • Able to communicate in Mandarin Chinese or Taiwanese.
  • Owns and is able to use a smartphone.
  • Endoscopically confirmed gastroesophageal reflux disease with Los Angeles (LA) Classification Grade B, C, or D erosive esophagitis, or Barrett's esophagus.
  • Able and willing to provide written informed consent.

You may not qualify if:

  • Previous esophageal or gastric surgery, including anti-reflux surgery.
  • Regular use of proton pump inhibitors within the previous 8 weeks.
  • Receiving antithrombotic therapy.
  • Diabetes mellitus requiring treatment (HbA1c ≥ 6.5%).
  • Liver cirrhosis (Child-Pugh class B or higher).
  • Chronic kidney disease stage 3 or higher.
  • Neurological disorders affecting participation.
  • Malignancy other than early-stage cancer.
  • Hiatal hernia larger than 2 cm.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yuan's General Hospital

Kaohsiung City, 80249, Taiwan

Location

MeSH Terms

Conditions

Gastroesophageal RefluxSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Study Officials

  • Yi-Hsuan Liu, Nurse Practitioner

    Fooyin University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants are randomly assigned to one of two parallel groups. The intervention group receives a mobile application in addition to standard education, while the control group receives standard education alone.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Nurse Practitioner

Study Record Dates

First Submitted

July 30, 2026

First Posted

August 4, 2026

Study Start

September 15, 2025

Primary Completion

February 16, 2026

Study Completion

February 16, 2026

Last Updated

August 5, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared because data sharing was not included in the study protocol or informed consent.

Locations